Table 1

Patient and control characteristics

Controls (n=27)pSS
IFNpos (n=21)IFNneg (n=14)
Demographics
 Female (%)24/27 (89)16/21 (76)12/14 (86)
 Mean age (years)*53±1157 (30–85)55 (37–76)
 Disease duration (years)*NA13.8±6.410.9±7.7
pSS manifestations (%)
 Ocular symptomsNA20/21 (95)14/14 (100)
 Oral symptomsNA21/21 (100)13/14 (93)
 Positive ocular testsNA15/21 (71)12/14 (86)
 Positive histopathologyNA11/21 (52)7/14 (50)
 Positive salivary gland testsNA1/21 (5)1/14 (7)
 Anti-SSANA20/21 (95)10/14 (71)
 Anti-SSBNA17/21 (81)6/14 (43)
Medication status (%)
 PilocarpineNA5/21 (24)4/14 (29)
 HydroxychloroquineNA13/21 (62)13/14 (93)
 CorticosteroidsNA1/21 (5)1/14 (7)
  • *Data are presented as means with corresponding range or SD.

  • IFNpos, IFN type I signature positive; IFNneg, IFN type I signature negative; NA, not applicable; pSS, primary Sjögren's syndrome.